After-hours trade on Thursday saw Bellicum Pharmaceuticals Inc. (BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, plunge -0.57% at $3.46. BLCM stock ended last trading session at $3.48, rising by 4.19%. BLCM stock was traded in a price range from $3.29 to $3.48.
Trading volume for BLCM stock was 0.13 million shares, lower than the daily average of 0.37 million shares over 100 days. Shares of BLCM have added 9.43% over the last five days, and 30.34% over the past month. Since the BLCM stock has stabilized in the absence of current news, we can go back to recent developments to gain a more comprehensive understanding of the company.
Is the BLCM going well?
Bellicum is a biopharmaceutical company developing controllable cell therapies as a cure for cancer. In addition to powerful CAR-T signaling technologies, BLCM’s future product candidates will produce more effective CAR-T cell therapies. BLCMP’s GoCAR-T product candidates, BPX-601 and BPX-603, aim to override immune inhibitory mechanisms by combining CAR-T cells with killer cells.
Last month, Bellicium also shared an operational update when reporting its first quarter financial results. As in the first quarter, BLCM focused on the clinical testing of its next-generation CAR-T cell therapy. Both BPX-601 and BPX-603 clinical trials for HER2+ solid tumors in prostate cancer are well underway, and BLCM anticipated future updates regarding both trials.
BLCM’s Program Highlights and Current Updates
BPX-601 and rimiducid have entered the Phase 1/2 dose-escalation clinical trial at BLCM evaluating candidates with metastatic pancreatic or prostate cancer.
Phase 1/2 clinical trial for BPX-603 was being conducted by BLCM in solid tumor patients.
Research looked at human epidermal growth factor 2 (HER2) and its role in breast, endometrial, ovarian, gastric, and colorectal cancers.
In a digital edition of Blood, an open access journal published by the American Society of Hematology, the first report on the use of the CaspaCIDe safety switch has been published by BLCM ahead-of-print.
In its report, BLCM describes a case from an investigator-sponsored trial performed at the Lineberger Comprehensive Cancer Center of the University of North Carolina involving autologous CAR-T cells expressing CD19 and CaspaCIDe.
When BLCM is planning to present trial data:
Bellicium (BLCM) plans to present BPX-601 and rimiducid data in the first quarter of 2022 for the treatment of metastatic castration-resistant prostate cancer. BLCM also expected to report the results of its Phase I trial for BPX-603 GoCAR-T during the fourth quarter of 2021.